The body's inflammatory response is crucial for combating invading pathogens, but sometimes this response spins out of control, leading to chronic disease or even death. Several recent studies now uncover transcriptional mechanisms that help to hold inflammation in check.
A rather extreme example of inflammatory overkill is sepsis, in which the body mounts an excessive and often deadly response to a microbial infection. Sepsis affects millions of people worldwide every year, and about half of the people with septic shock end up dying of massive organ failure. A study in Science led by Ivan Marazzi now finds that drugs that inhibit topoisomerase 1 (Top1), an enzyme best known for unwinding DNA, can protect mice from lethal bacterial infection (Rialdi et al., 2016) . When pathogens invade, the innate immune system recognizes microbial molecules and turns on immune response genes that kick off an inflammatory response. The authors show that in response to microbial infection, Top1 controls the activity of RNA polymerase II at immune response genes, particularly those that require nucleosome remodeling for activation. To mimic what happens when patients are hospitalized with a viral infection and then acquire a bacterial co-infection, the authors inoculated mice with flu virus and then challenged them with a lethal dose of staph bacteria. Remarkably, when these mice were treated with a chemical inhibitor of Top1 before the staph co-infection, they were protected from death. Top1 inhibition also prevented mice injected with bacterial endotoxin from dying, suggesting a relatively broad dampening of inflammation.
These findings could have potential therapeutic applications for populations most strongly at risk for sepsis, such as elderly or young patients in hospitals or other acute care environments. Another possibility would be to target mechanisms that resolve inflammation, and as it turns out, this process is also transcriptionally controlled at the chromatin level, as shown in a study from Xuetao Cao's group demonstrating that transcriptional repression of cytokine expression by Tet2 is needed to wind down the inflammatory response in mice (Zhang et al., 2015) .
The body also has its own mechanisms for preventing the immune response from kicking in, as shown by a study led by Kate Fitzgerald in this issue of Cell (Atianand et al., 2016) . While Top1 promotes transcription of inflammatory genes by regulating chromatin, Atianand et al. found that a long noncoding RNA (lncRNA) does the opposite-it acts as a brake to prevent inflammation in mouse macrophages, by modifying the position of nucleosomes at immune response genes and suppressing their transcription. Mice lacking lincRNA-EPS showed higher baseline levels of immune genes than wild-type animals, as well as higher cytokine and immune protein levels than normal after being injected with lipopolysaccharide (LPS), which triggers a massive, sepsis-like inflammatory response, indicating that this lncRNA mechanism keeps inflammation in check both during homeostasis and following microbial challenge. Strikingly, mutant mice succumbed more readily to what would normally be a non-lethal dose of LPS treatment. It isn't clear whether lincRNA-EPS has a human counterpart, but since lncRNA sequences are generally poorly conserved across species, the study's identification of a motif in lincRNA-EPS that interacts with the RNA binding protein hnRNPL, whose knockdown similarly derepresses immune gene expression, may be informative for future studies.
Of course, unrestrained inflammation doesn't always cause imminent death, but more modest responses can lead to chronic disease. For instance, in people with celiac disease, eating gluten triggers an immune response that leads to a variety of symptoms, such as anemia, bone loss, and gastrointestinal distress. Recent work reported in Science by Sankar Ghosh and colleagues now implicates a lncRNA in this process (Castellanos-Rubio et al., 2016) . The authors mapped a disease-linked single nucleotide polymorphism (SNP) to lnc13, which they found interacts with the RNA binding protein hnRNPD to suppress expression of inflammatory genes dyregulated in celiac disease, likely through modulating chromatin. Intestinal biopsies from celiac disease patients showed decreased lnc13 levels, and the disease-associated lnc13 variant is impaired in its binding to hnRNPD, pointing to a possible disease mechanism.
The studies from Fitzgerald and Ghosh show that lncRNAs play an important role in restraining the transcription of innate immune response genes and preventing inflammation. In both cases, the lncRNA responds to inflammatory signals triggered by microbes and binds to an hnRNP to effect its function, but it's unclear at this point how much the two mechanisms may overlap, as they appear to regulate somewhat different sets of inflammatory genes. Indeed, lnc13 seems to suppress expression of just a subset of inflammatory genes dysregulated in celiac disease, and it's tempting to speculate that different lncRNAs may be responsible for regulating distinct modules of immune response genes, allowing for fine regulatory control. However, further work will be needed to investigate this possibility. Together with the recent studies from Marazzi, Cao, and others, a picture seems to be emerging in which the genes responsible for effecting inflammation are tightly transcriptionally regulated at the chromatin level, providing possible entry points for therapeutic interventions to rein in excess innate immune responses in disease.
